ERS Genomics and IRBM sign CRISPR/Cas9 license agreement

From ERS Genomics May 21 2024 ERS Genomics Limited , the CRISPR licensing Company, and IRBM, a leader in the field of drug discovery , today announced a non-exclusive CRISPR / Cas9 license agreement. The agreement grants IRBM access to ERS’ CRISPR / Cas9 patent portfolio.

IRBM is a drug discovery CRO with expertise ranging from target validation and hit finding to preclinical candidate nomination across various therapeutic areas, including oncology, infectious diseases, and neuroscience. The company has contributed to the discovery and development of four marketed therapeutics for HIV, HCV, ovarian cancer, and cutaneous T-cell lymphoma.

Carlo Toniatti, MD, PhD, CSO, IRBM, said: “We are committed to delivering high quality drugs by leveraging our broad range of expertise and capabilities across the entire preclinical drug discovery continuum. With the integration of CRISPR/Cas9 gene editing technology we are increasing our capability to identify and validate potential drug targets, to generate more predictive pre-clinical models and to elucidate the mechanisms of action of novel therapeutics.

We are committed to supporting cutting-edge research and expanding the horizons of medical innovation by providing companies such as IRBM with the ability to take advantage of CRISPR/Cas9 technology. We look forward to seeing the innovative ways in which our gene editing technology will be utilized in various stages of drug discovery, providing candidates for a wide range of therapeutic areas.

Source: News Formal (newsformal.com)

CRISPR Genomics Drug Discovery Gene Preclinical Technology Therapeutics

United Kingdom Latest News, United Kingdom Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

ERS Genomics appoints John E Milad as Chief Executive OfficerERS Genomics Limited (‘ERS’), the CRISPR licensing company, today announced the appointment of John E Milad as CEO, with immediate effect. John brings over 25 years of experience as an executive leader, venture capitalist, and investment banker focused on the life sciences and medical technology sectors.
Source: NewsMedical - 🏆 19. / 71 Read more »

Enhanc3D Genomics appoints Hazel Jones as Chief Executive OfficerEnhanc3D Genomics, a company developing disruptive technologies to unlock the 3D genome for use in novel target identification and unique patient stratification, today announced the appointment of Hazel Jones as Chief Executive Officer, after a successful six-month tenure as interim CEO and COO.
Source: NewsMedical - 🏆 19. / 71 Read more »

Azenta opens the doors to its new genomics laboratory in Oxford, UKAzenta, Inc. today announced the grand opening of the new Genomics Laboratory in Oxford, UK, expanding its global reach of GENEWIZ Multiomics & Synthesis Solutions further in the UK market.
Source: NewsMedical - 🏆 19. / 71 Read more »

Beckman Coulter Life Sciences and Watchmaker Genomics Collaborate to Deliver NGS Library Preparation SolutionsCollaboration Helps Simplify Lab Operations and Improve Data Quality for Users.
Source: NewsMedical - 🏆 19. / 71 Read more »

Genomics plc and GSK collaborate to harness polygenic risk scores in clinical trialsGenomics plc and GSK announced a new collaboration to explore the potential for using polygenic risk scores (PRS) in clinical trials, to improve understanding of disease risk and patient selection, which could support optimization of trial design.
Source: NewsMedical - 🏆 19. / 71 Read more »

Gene expression and bioinformatics tools to optimize cancer therapyIn the field of biomedical research and genomics, the advancement of bioinformatics technologies and tools is opening new frontiers in the understanding of diseases and their diagnosis and treatment.
Source: medical_xpress - 🏆 101. / 51 Read more »